Printer Friendly
The Free Library
23,403,340 articles and books


Creative BioMolecules, Inc. Announces Stryker's Submission of OP-1 Implant for Approval in the United States and Europe.

BOSTON--(BW HealthWire)--June 7, 1999--

Creative BioMolecules, Inc. (Nasdaq:CBMI) announced today that Stryker Corp. (NYSE:SYK), its partner in orthopaedic and dental reconstruction, has submitted applications in both the United States and Europe seeking marketing approval for the OP-1 bone graft device, also known as the OP-1 Implant(TM).

In a news release issued this afternoon, Stryker stated that they have "submitted the final module of its Pre-Market Approval (PMA) to the U.S. Food and Drug Administration (FDA) and has also submitted a Marketing Authorization Application (MAA) in Europe to the European Medicines Evaluation Agency (EMEA) for its OP-1 Implant(TM). Both submissions seek approval for the OP-1 Implant(TM) to treat long bone nonunions. The FDA and the EMEA have up to 45 days to decide if the submissions are acceptable for filing. The Company (Stryker) can give no assurance that the submissions will be accepted and, if accepted as filings, that approval for any use of the OP-1 Implant(TM) will be obtained."

Creative BioMolecules, Inc. is a leader in the understanding of tissue formation and repair through the activity of morphogenic proteins.

This news release includes forward-looking statements that involve risks and uncertainties. Factors which could cause actual results to differ from the Company's expectations include, without limitation, the course of the research and development programs, including the achievement of development milestones by the Company and/or its partners, the inability to partner programs, the initiation, progress and completion of clinical testing, the impact of competitive products, the timely receipt of regulatory clearances required for clinical testing, manufacturing and marketing of products, including acceptance of submissions by regulatory agencies, and the other risks and uncertainties detailed from time to time in the Company's periodic reports.

NOTE: Creative BioMolecules' news releases are available on the Internet at http://www.creativebio.com.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4E
Date:Jun 7, 1999
Words:306
Previous Article:Micron Technology Ships 128 MEG and 144 MEG RDRAM Samples.
Next Article:ADD+ON Offers Canadian Software Solution; New Custom Program Aids ADD+ON Payroll Providers in Canada.
Topics:



Related Articles
Focusing the soul's fuzzy window.
Ingenuity helps transform eyesore to chic storefront.
Biotechnology may fortify U.S. Army.
FDA APPROVES BROADER USE OF ELECTRICAL HEART DEVICE.
Recession? What recession? Southern gentleman John Brown achieves 20 percent earnings growth annually--no matter what. (Profile).
FDA MAY LIFT BAN ON SILICONE BREAST IMPLANTS TRACKING RECIPIENTS' HEALTH FOR 10 YEARS RECOMMENDED.
Tissue tether: improved conducting plastic could boost nerve-regeneration success.
Ventracor Investor Update March 2007.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters